Skip to main content
Zhejiang Hisun Pharmaceutical Co.,Ltd. logo

Zhejiang Hisun Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 600267 ISIN · CNE0000013Z2 LEI · 3003000GJUOZ7ASHZM53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,994 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600267

About Zhejiang Hisun Pharmaceutical Co.,Ltd.

https://www.hisunpharm.com/

Zhejiang Hisun Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates across multiple therapeutic categories, including oncology, anti-infectives, cardiovascular diseases, endocrinology, and immunosuppressants. Its technical capabilities span chemical synthesis, microbial fermentation, and biotechnology. As a significant global supplier, the company maintains rigorous quality management systems compliant with international standards, including US FDA and EU GMP. The product portfolio includes a diverse array of specialized medications and raw materials intended for global distribution. By integrating large-scale production with advanced R&D, the company provides a broad spectrum of therapeutic solutions to healthcare providers and pharmaceutical partners worldwide.

Recent filings

Filing Released Lang Actions
浙江海正药业股份有限公司关于获得药品注册证书的公告
Regulatory Filings Classification · 84% confidence The document is a corporate announcement in Chinese informing investors that the Company has received a drug registration certificate from the National Medical Products Administration. It does not contain financial statements, earnings highlights, proxy materials, or any report publication. It is a routine regulatory notice of a non‐financial event. Therefore it best fits under “Regulatory Filings (RNS).”
2026-05-21 Chinese
浙江海正药业股份有限公司关于子公司获得兽药产品批准文号批件的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Zhejiang Haizheng Pharmaceutical Co., Ltd. regarding its subsidiary obtaining approval certificates for veterinary drug products from the Ministry of Agriculture and Rural Affairs of China. It details the approval numbers, product specifications, and intended uses of the veterinary drugs. The document is a formal public disclosure about regulatory approval of products, not a financial report, earnings release, or management discussion. It does not contain financial data, management changes, voting results, or legal proceedings. It is a regulatory announcement about product approvals, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-11-06 Chinese
浙江海正药业股份有限公司关于召开2025年第二次临时股东会的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the convening of the 2025 second extraordinary general meeting (临时股东会) of Zhejiang Hisun Pharmaceutical Co., Ltd. It includes information about the meeting date, voting methods, agenda items, shareholder eligibility, registration procedures, and proxy authorization. It does not contain financial statements, audit results, or detailed financial data. It is not a report itself but an announcement about the meeting and voting procedures. The document length is 3221 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories like AGM Information or Declaration of Voting Results, since it is a notice prior to the meeting rather than materials or results from the meeting.
2025-11-05 Chinese
浙江海正药业股份有限公司2025年第二次临时股东会资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2025 Second Extraordinary General Meeting of Shareholders" of Zhejiang Haizheng Pharmaceutical Co., Ltd. It contains detailed agenda items, including proposals for investment in another company and the establishment of a joint venture. The document includes meeting procedures, voting instructions, and legal witness statements. It is clearly a set of materials prepared for a shareholders meeting, not a report or announcement of financial results or other filings. The content is consistent with materials shared during a shareholders meeting, which aligns with the definition of AGM Information (AGM-R). The document length (8954 characters) supports it being a full meeting material rather than a brief announcement. Therefore, the classification is AGM Information (AGM-R) with high confidence.
2025-11-05 Chinese
浙江海正药业股份有限公司关于第四次以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Zhejiang Haizheng Pharmaceutical Co., Ltd. regarding the progress of its fourth share repurchase plan through centralized bidding transactions. It details the repurchase scheme, including dates, amounts, prices, and progress updates on shares repurchased. The document is relatively short (1388 characters) and focuses on the company's share buyback activity, not on financial results or other report types. This matches the definition of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares.
2025-11-03 Chinese
浙江海正药业股份有限公司关于公司参与全国药品集中采购拟中标的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Zhejiang Haizheng Pharmaceutical Co., Ltd. regarding the company's participation and proposed winning in the national centralized drug procurement. It details the products involved, their specifications, prices, and the potential impact on the company. The document is relatively short (1825 characters) and serves as a public disclosure of a business event rather than a financial report or detailed analysis. It does not contain financial statements, audit information, or management discussion. It is not a report publication announcement since it contains substantive content about the procurement results and impact. This type of announcement fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-29 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.